NF-κB: a new player in angiostatic therapy
Open Access
- 19 February 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 11 (1), 101-106
- https://doi.org/10.1007/s10456-008-9094-4
Abstract
Angiogenesis is considered a promising target in the treatment of cancer. Most of the angiogenesis inhibitors in late-stage clinical testing or approved for the treatment of cancer act indirectly on endothelial cells. They either neutralize angiogenic growth factors from the circulation or block the signaling pathways activated by these growth factors. Another group of angiogenesis inhibitors are the direct angiostatic compounds. These agents have a direct effect on the endothelium, affecting cellular regulatory pathways, independently of the tumor cells. The reason that this category of agents is lagging behind regarding their translation to the clinic may be the lack of sufficient knowledge on the mechanism of action of these compounds. The transcription factor NF-κB has been recently connected with multiple aspects of angiogenesis. In addition, several recent studies report that angiogenesis inhibition is associated to NF-κB activation. This is of special interest since in tumor cells NF-κB activation has been associated to inhibition of apoptosis and currently novel treatment strategies are being developed based on inhibition of NF-κB. The paradigm that systemic NF-κB inhibition can serve as an anti-cancer strategy, therefore, might need to be re-evaluated. Based on recent data, it might be speculated that NF-κB activation, when performed specifically in endothelial cells, could be an efficient strategy for the treatment of cancer.Keywords
This publication has 66 references indexed in Scilit:
- NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancerJCI Insight, 2006
- Prolactin/growth hormone–derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesisProceedings of the National Academy of Sciences of the United States of America, 2006
- Nuclear factor-κB in cancer development and progressionNature, 2006
- NF-κB inhibition: A double-edged sword in cancer?European Journal Of Cancer, 2006
- Vascular endothelial growth factor signalling in endothelial cell survival: A role for NFκBBiochemical and Biophysical Research Communications, 2006
- Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agentBiochemical and Biophysical Research Communications, 2004
- To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosisOncogene, 2003
- NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasiaNature, 2003
- Tumor angiogenesis factors reduce leukocyte adhesion in vivoInternational Immunology, 2000
- Angiostatin Upregulates E-Selectin in Proliferating Endothelial CellsBiochemical and Biophysical Research Communications, 1998